NetraMark Signs Contract with AlgoTx to Enhance Clinical Trial Design for ATX01

Core Insights - NetraMark Holdings Inc. has entered into a partnership with AlgoTherapeutix SAS to utilize its NetraAI platform for analyzing patient-level data from AlgoTx's ATX01 program, aimed at enhancing clinical trial design for chemotherapy-induced peripheral neuropathy (CIPN) [1][2][3] Company Overview - NetraMark is focused on developing Generative Artificial Intelligence (Gen AI) and Machine Learning (ML) solutions for the pharmaceutical industry, utilizing a novel topology-based algorithm to analyze patient data [6] - AlgoTherapeutix is a clinical-stage biotechnology company developing a first-in-class therapeutic for peripheral neuropathic pain, specifically targeting chemotherapy-induced peripheral neuropathy with its lead asset, ATX01 [8][9] Partnership Details - The collaboration will leverage NetraAI's technology to explore drug and placebo response variables, identify responder personas, and develop enrichment strategies for future ATX01 trials [2][4] - NetraMark will create customized AI models and interactive tools to assist AlgoTx in testing hypotheses and characterizing patient subpopulations, aiming to generate validated and regulator-ready insights [5][4] Product Information - ATX01 is a proprietary topical formulation of amitriptyline designed to provide targeted relief from pain associated with CIPN, which affects 68% of cancer treatment patients [9][10] - The product has received FDA fast track development status, indicating its potential significance in addressing a high unmet medical need [9] Financial Background - AlgoTx raised EUR 20 million in a Series B funding round in 2023, bringing its total funding to EUR 35 million, supported by a consortium of investors [11]